Abstract Objective: Evidence is accumulating that components of the Cannabis sativa plant may have therapeutic potential in treating psychiatric disorders. Medicinal cannabis (MC) products are legally available for prescription in Australia, primarily through…
Condition: Mental Disorders
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Abstract The endocannabinoid system shows promise as a novel target for treating psychiatric conditions. Cannabidiol (CBD), a naturally occurring cannabinoid, has been investigated in several psychiatric conditions, with diverse effects…
Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status
Please use this link to access this publication. Abstract Background: Cannabis can induce negative outcomes among consumers with mental health conditions. This study examined medical help-seeking behavior, patterns of adverse effects,…
Association of cannabis potency with mental ill health and addiction: a systematic review
Please use this link to access this publication. Summary Cannabis potency, defined as the concentration of Δ9-tetrahydrocannabinol (THC), has increased internationally, which could increase the risk of adverse health outcomes…
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review
Abstract We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were…
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
Please use this link to access this publication. Abstract Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are the most represented phytocannabinoids in Cannabis sativa plants. However, CBD may present with a different activity…
Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?
Abstract A position statement developed by the Canadian Psychiatric Association’s (CPA) Research Committee and approved by the CPA’s Board of Directors on May 13, 2020.
Association between formal thought disorder and cannabis use: a systematic review and meta-analysis
Abstract Formal thought disorder (FTD) is a multidimensional syndrome mainly occurring along the psychosis continuum. Cannabis use is known to increase symptoms of psychosis, particularly positive symptoms. However, the impact…
Prospects for the Use of Cannabinoids in Psychiatric Disorders
Please use this link to access this publication. Abstract Increasing evidence suggests an essential role of the endocannabinoid system in modulating cognitive abilities, mood, stress, and sleep. The psychoactive effects…
Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials
Please use this link to access this publication. Abstract The utility of cannabinoids and cannabinoid-based products (CBPs) as a pharmacological aid to treat psychiatric disorders in adulthood is still poorly…